Latest Breaking News On - Voltron therapeutics inc - Page 3 : comparemela.com

Hoth Therapeutics Provides Operational Update on Novel Therapeutic Pipeline News provided by Share this article Share this article NEW YORK, Feb. 2, 2021 /PRNewswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company today is providing shareholders with an update on its pipeline of novel therapeutics targeting dermatological, COVID-19 and support care indications. Drug Pipeline Highlights: HT-001: Granted Pre-IND meeting with FDA with responses targeted for February 22, 2021 HT-003: Received positive preclinical mechanism of action date for acne treatment and renewal of the preclinical research plan HT-004: Key proof-of-concept animal model data expected in Q2 2021 Mr. Robb Knie, Chief Executive Officer of Hoth, commented,  Hoth s entire pipeline of innovative novel therapeutics have made significant progress throughout their developmental process over the course of the last year.  During that time, we have been able to strengthen our balance shee

Charles riverUnited statesHalovax vaxcelerateRobb knieWalter reed army institute of researchVoltron therapeutics incHuman research ethics committeeVirginia commonwealth universityDrug administrationLr advisorsHoth therapeutics incArmy medical researchExchange commissionTherapeutics incDevelopment commandPrnewswire hoth therapeutics inc